Relay Therapeutics, Inc. (RLAY) - Dilution Analysis

10-Q filing | 179.8M shares outstanding

10-Q filing | 172.4M shares outstanding

10-Q filing | 171.3M shares outstanding

10-Q filing | 169.2M shares outstanding

10-K filing | 169.5M shares outstanding

10-Q filing | 167.4M shares outstanding

10-Q filing | 132.8M shares outstanding

10-Q filing | 130.8M shares outstanding

10-K filing | 122.6M shares outstanding

8-K filing: Relay Therapeutics, Inc. entered into a securities purchase agreement for the private placement of 2,500,000 shares of common stock at $12.00 per share, with gross proceeds of approximately $30 million. ($30.0M proceeds)

10-Q filing | 122.2M shares outstanding

10-Q filing | 121.7M shares outstanding

10-Q filing | 121.3M shares outstanding

10-K filing | 112.2M shares outstanding

10-Q filing | 110.9M shares outstanding

8-K filing: Relay Therapeutics, Inc. announced an underwritten public offering of 11,320,755 shares of common stock at a price of $26.50 per share, with an option for the underwriters to purchase an additional 1,698,113 shares. ($284.5M proceeds)

10-Q filing | 108.9M shares outstanding

10-Q filing | 108.7M shares outstanding

10-K filing | 108.3M shares outstanding

10-Q filing | 108.0M shares outstanding

8-K filing: Relay Therapeutics, Inc. completed a public offering of 13,207,547 shares of common stock at $26.50 per share, with underwriters exercising their option to purchase an additional 1,981,132 shares. ($399.9M proceeds)

10-Q filing | 92.7M shares outstanding

10-Q filing | 92.4M shares outstanding

S-1 filing: This S-1 filing discusses potential U.S. federal income tax implications for non-U.S. holders of common stock and details the sale of 1,883,487 shares of common stock by selling stockholders.

10-K filing | 90.4M shares outstanding

10-Q filing | 90.0M shares outstanding

10-Q filing | 4.6M shares outstanding

S-1/A filing: This is an S-1/A (Amendment No. 4) filing for Relay Therapeutics, Inc. registering common stock with a proposed maximum offering price of $437,000,000, covering 23,000,000 shares at $19.00 per share, including an underwriter option to purchase 3,000,000 shares.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. The company is offering 20,000,000 shares of common stock, with an additional 3,000,000 shares available to underwriters. The company estimates net proceeds to be $341.1 million or $392.7 million if the option is exercised in full assuming an IPO price of $18.50. After the offering, there will be 86,875,742 shares of common stock outstanding.

S-1/A filing: Relay Therapeutics, Inc. is offering 14,700,000 shares of common stock in an S-1/A filing, with an additional 2,205,000 shares available to underwriters, estimating net proceeds of $229.4 million, intending to use the funds for drug discovery, clinical development, and manufacturing platform expansion.

S-1/A filing: This S-1/A filing details the offering of common stock at an initial public offering price of $17.00 per share. The company intends to use the net proceeds from this offering to fund drug discovery and clinical development efforts as well as further expansion of our manufacturing platform and capabilities, and infrastructure to support our pipeline.

S-1 filing: This is an S-1 filing for an initial public offering of common stock.